Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
Royalty Pharma plc (RPRX) is set to report its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time. Investors can access the conference call information and live webcast on the company's website. A replay will be available for at least 30 days.
01/30/2024 - 04:15 PM
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Pfizer’s Nurtec ODT, Gilead’s Trodelvy, and 12 development-stage product candidates. For more information, visit www.royaltypharma.com .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637ir@royaltypharma.com
When will Royalty Pharma plc report its Q4 and full year 2023 financial results?
Royalty Pharma plc (RPRX) will report its Q4 and full year 2023 financial results on February 15, 2024.
What time will the conference call and webcast be held?
The conference call and webcast will be held at 8:00 a.m. Eastern Time.
Where can investors access the conference call information and live webcast?
Investors can access the conference call information and live webcast on the company's website at https://www.royaltypharma.com/investors/events/.
How long will the replay of the conference call and webcast be available?
The replay of the conference call and webcast will be available on the company's website for at least 30 days.
RPRX Rankings
#4238 Ranked by Stock Gains
RPRX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
New York
About RPRX
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi